公开(公告)号：US11439754B1

公开(公告)日：2022-09-13

申请号：US17539270

申请日：2021-12-01

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor ,  Ashutosh Zade

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

Abstract: Disclosed herein is a method for execution by a drug delivery device for determining an optimal dose of a liquid drug for current cycle of a medication delivery algorithm, the method utilizing a stepwise evaluation of a model and a cost function across a coarse search space consisting of coarse discrete quantities of the drug and a refined search space consisting of refined discrete quantities of the drug.

公开(公告)号：US12300375B2

公开(公告)日：2025-05-13

申请号：US18151582

申请日：2023-01-09

Applicant: INSULET CORPORATION

Inventor： David Nazzaro ,  Steven Cardinali ,  Nicholas Conte ,  Daniel Allis ,  Jason O'Connor ,  Joon Bok Lee ,  Ashutosh Zade ,  Timothy Henning ,  Thomas Metzmaker ,  Ian McLaughlin

IPC: G16H20/60 ,  G16H20/17

Abstract: Disclosed are examples of a device, a system, methods and computer-readable medium products operable to implement functionality to determine and respond to a purpose of a meal. An algorithm or application may receive data that may include data related to a meal purpose from data sources and determine whether any of the data received from the plurality of data sources was received from a direct data source or an indirect data source. The data may be evaluated to determine a purpose of the meal. Based on the results of the evaluation, instructions may be generated to provide an appropriate response based on the determined purpose of the meal. The generated instructions to provide the appropriate response based on the determined purpose of the meal may be output.

公开(公告)号：US11986630B2

公开(公告)日：2024-05-21

申请号：US16788892

申请日：2020-02-12

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor ,  Trang Ly ,  Yibin Zheng ,  Connor Gullifer ,  Kyle Grover

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  A61M2202/07 ,  A61M2205/18 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/583 ,  A61M2230/201

Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.

公开(公告)号：US11957875B2

公开(公告)日：2024-04-16

申请号：US17112314

申请日：2020-12-04

Applicant: INSULET CORPORATION

Inventor： Yibin Zheng ,  Joon Bok Lee ,  Steven Cardinali ,  Jason O'Connor ,  Eric Benjamin ,  Ian McLaughlin ,  David Nazzaro ,  Ashutosh Zade

IPC: A61M5/172 ,  A61M5/142 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70

CPC classification number: A61M5/1723 ,  A61M5/14248 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70 ,  A61M2005/1726 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

公开(公告)号：US11383035B1

公开(公告)日：2022-07-12

申请号：US17539270

申请日：2021-12-01

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Yibin Zheng ,  Jason O'Connor ,  Ashutosh Zade

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

Abstract: Disclosed herein is a method for execution by a drug delivery device for determining an optimal dose of a liquid drug for current cycle of a medication delivery algorithm, the method utilizing a stepwise evaluation of a model and a cost function across a coarse search space consisting of coarse discrete quantities of the drug and a refined search space consisting of refined discrete quantities of the drug.

公开(公告)号：US12121701B2

公开(公告)日：2024-10-22

申请号：US17582349

申请日：2022-01-24

Applicant: Insulet Corporation

Inventor： Joon Bok Lee ,  Jason O'Connor ,  Yibin Zheng ,  Ashutosh Zade

IPC: G16H20/17 ,  A61B5/00 ,  A61B5/145 ,  A61K38/22 ,  A61K38/26 ,  A61K38/28 ,  A61M5/14 ,  A61M5/142 ,  A61M5/172 ,  G16H40/67

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61B5/4839 ,  A61B5/4866 ,  A61B5/7282 ,  A61K38/22 ,  A61K38/26 ,  A61K38/28 ,  A61M5/1408 ,  A61M5/14248 ,  G16H20/17 ,  G16H40/67 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2230/201

Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.

公开(公告)号：US11324889B2

公开(公告)日：2022-05-10

申请号：US16791648

申请日：2020-02-14

Applicant: Insulet Corporation

Inventor： Yibin Zheng ,  Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor

IPC: A61M5/172 ,  G06F17/17

Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

公开(公告)号：US20220062552A1

公开(公告)日：2022-03-03

申请号：US17446084

申请日：2021-08-26

Applicant: Insulet Corporation

Inventor： Ashutosh Zade ,  Jay Jantz ,  Yibin Zheng ,  Trang Ly ,  Joon Bok Lee ,  Jason O'connor ,  Ian Mclaughlin ,  Nicholas Conte ,  Steven Cardinali

IPC: A61M5/172 ,  G16H20/17

Abstract: Exemplary embodiments may perform data analytics on data regarding a user of a medicament delivery device and data regarding other users of like medicament delivery devices to provide insights and guide management of the medicament delivery device for the user. The data analytics may be so called “big data” analytics that are performed on large data sets. The data analytics may be performed on various types of data to help determine what actions, if any, the remote management should take. The data analytics may be performed by the software on the remote management device or by other computational resources, such as by other servers or cloud computing resources. Exemplary embodiments may provide for remote management of a medicament delivery device. The management may be remote in that the management is performed via a remote management device, such as a computing device, that is remotely located from the medicament delivery device.

公开(公告)号：US12226612B2

公开(公告)日：2025-02-18

申请号：US17715589

申请日：2022-04-07

Applicant: INSULET CORPORATION

Inventor： Yibin Zheng ,  Joon Bok Lee ,  Ashutosh Zade ,  Jason O'Connor

IPC: A61M5/172 ,  G06F17/17

Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.

公开(公告)号：US11628251B2

公开(公告)日：2023-04-18

申请号：US16586440

申请日：2019-09-27

Applicant: INSULET CORPORATION

Inventor： Jason O'Connor ,  Joon Bok Lee ,  Trang Ly ,  Todd Vienneau ,  Yibin Zheng ,  Ashutosh Zade

IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.